Paul Bisaro's Trading History
| MYGNMyriad Genetics | Jun 05, 2026 | Director | Uninformative Buy | ― | $997.85K | |
| ZTSZoetis | May 13, 2026 | Director | Informative Buy | 151.74K | $2.22M | |
| MNKTQMallinckrodt public limited company | Jun 29, 2023 | ― | Uninformative Sell | 4.72K | $3.85K | |
| TXMDTherapeuticsMD | Aug 22, 2022 | Director | Uninformative Buy | 20.28K | $10.66K | |
| AMRXAmneal Pharmaceuticals | May 09, 2019 | EC, Director | Uninformative Buy | 167.38K | $633.56K | |
| AGNAllergan | Mar 06, 2018 | ― | Uninformative Sell | 434.44K | $73.80M | |
| ZBHZimmer Biomet Holdings | ― | Director | ― | $0.00 |
You May Also Like
Paul Bisaro insider profile FAQ
What is the percentage of profitable transactions made by Paul Bisaro?
The percentage of profitable transactions made by Paul Bisaro is 40%.
What is the average return per transaction made by Paul Bisaro?
The average return per transaction made by Paul Bisaro is -16.00%.
What stocks does Paul Bisaro hold?
Paul Bisaro holds: MYGN, AGN, TXMD, AMRX, MNKTQ, ZBH, ZTS stocks.
What was Paul Bisaro's most profitable transaction?
Paul Bisaro’s most profitable transaction was an Informative Buy of MYGN stock on May 14, 2026. The return on the trade was 75.40%.
What is Paul Bisaro's role in Myriad Genetics?
Paul Bisaro's role in Myriad Genetics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.